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Abstract
Background: Mutations in the TERT promoter, ALK rearrangement, and the BRAF V600E mutation are associated
with aggressive clinicopathologic features in thyroid cancers. However, little is known about the impact of TERT
promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of BRAF mutations.
Methods: We performed Sanger sequencing to detect BRAF V600E and TERT promoter mutations and both
immunohistochemistry and fluorescence in situ hybridization to identify ALK rearrangement on 243 thyroid cancers.
Results: TERT promoter mutations were not present in 192 well-differentiated thyroid carcinomas (WDTC) without
distant metastasis or in 9 medullary carcinomas. However, the mutations did occur in 40 % (12/30) of WDTC with
distant metastasis, 29 % (2/7) of poorly differentiated carcinomas and 60 % (3/5) of anaplastic carcinomas. ALK
rearrangement was not present in all thyroid cancers. The BRAF V600E mutation was more frequently found in
WDTC without distant metastasis than in WDTC with distant metastasis (p = 0.007). In the cohort of WDTC with
distant metastasis, patients with wild-type BRAF and TERT promoter had a significantly higher response rate after
radioiodine therapy (p = 0.024), whereas the BRAF V600E mutation was significantly correlated with progressive
disease (p = 0.025).
Conclusions: The TERT promoter mutation is an independent predictor for distant metastasis of WDTC, but ALK
testing is not useful for clinical decision-making in Korean patients with a high prevalence of the BRAF V600E
mutation. Radioiodine therapy for distant metastasis of WDTC is most effective in patients without BRAF V600E
and TERT promoter mutations.
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Background
Thyroid cancer is the most common type of endocrine
tumor, with an incidence that has significantly increased
in the last few decades [1, 2]. Although well-differentiated
thyroid carcinoma (WDTC) is one of the most curable of
all cancers, approximately 10–20 % of patients with
WDTC suffer from disease recurrence after surgery, and
some eventually die from the disease [3–5]. Various risk
stratification methods have been used for the proper
management of patients with WDTC; however, none are
completely accurate [6].
Molecular biomarkers have been used as an adjunct
diagnostic marker of thyroid cancer and a predictor of
patient prognosis [7, 8]. The BRAF V600E mutation is the
most common mutation in thyroid cancer, particularly in
papillary thyroid carcinoma (PTC), and plays an important
role in tumorigenesis and progression [9–14]. In Korea,
PTC comprises 97.3 % of all thyroid cancers according to
new data from the 2014 annual report of cancer statistics
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in Korea (http://www.cancer.go.kr/). The BRAF V600E
mutation is highly prevalent in Korean PTC patients [11].
Currently, there is controversy regarding whether the
BRAF V600E mutation is associated with poor prog-
nosis and aggressive clinicopathologic features in Ko-
rean PTC patients; therefore, additional prognostic
biomarkers to predict a more aggressive disease are
needed [9, 15–18].
Somatic mutations of the promoter region of the TERT
gene have been reported in various cancers, including thy-
roid cancers, but are not found in normal cells [19–23].
The frequent cytosine-to-thymine transition of the TERT
promoter region occurs at the following positions of
chr5: 1 295 228 (C228T) and 1 295 250 (C250T),
which correspond to nucleotide changes -124 bp (c.-
124C > T) and -146 bp (c.-146C > T) upstream from
the ATG start site, respectively (Fig. 1) [19–23]. These
TERT promoter mutations stimulate TERT transcriptional
activity in cancer cells [19–23]. In thyroid cancers, TERT
promoter mutations were predominantly found in more
aggressive disease, such as tall cell variant PTC,
widely invasive follicular thyroid carcinoma (FTC),
poorly differentiated carcinoma, and anaplastic carcin-
oma [13, 18, 21, 24, 25].
ALK gene rearrangements have recently been identified
in thyroid cancer [26–30]. EML4, STRN, TFG, and
GTF2IRD1 have been reported as ALK fusion partners
[27, 28, 30–32]. The prevalence of ALK-rearranged PTCs
has been reported to be up to 2.2 %, although the number
of study cases is limited [26]. A previous study reported
that ALK rearrangements were more frequently found in
aggressive thyroid cancer, while another study found
mutations only in unselected consecutive PTC cases and
not in aggressive disease, such as PTCs with distant me-
tastasis, poorly differentiated carcinomas and anaplastic
carcinomas [26, 28].
We aimed to investigate the prevalence of TERT pro-
moter and ALK mutations in thyroid cancer patients
Fig. 1 Structure of the wild-type TERT gene and representative sequencing electropherograms of the genomic DNA of the TERT promoter.
The g.1295228 C > T (C228T) and g.1295250 C > T (C250T) mutations within the TERT promoter gene result in a cytosine-to thymine transition at
124 bp (c.-124C > T) and 146 bp (c.-146C > T) upstream of the ATG start codon, respectively. g.1295228 C > A (C228A) is a cytosine-to adenine
transition at the 1 295 228 position of chr5
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with a high prevalence of the BRAF V600E mutation




We retrospectively enrolled 243 patients who underwent
thyroid surgery for thyroid cancer at Seoul St. Mary’s
Hospital of The Catholic University of Korea with the
approval of the Institutional Review Board. Informed
consent was obtained from every patient. The thyroid
cancers studied included 192 consecutive WDTCs without
distant metastasis (consisting of 127 classic PTCs, 11 clas-
sic PTCs with tall cell features, 9 encapsulated follicular
variant PTCs, 7 infiltrative follicular variant PTCs, 16 tall
cell variant PTCs, 1 oncocytic PTC, 1 Warthin-like PTC,
and 20 minimally invasive FTCs), 30 consecutive WDTCs
with distant metastasis (consisting of 14 classic PTCs, 4
classic PTCs with tall cell features, 1 encapsulated follicu-
lar variant PTC, 1 macrofollicular variant PTC, 5 tall cell
variant PTCs, 1 columnar cell variant PTC, 1 diffuse scler-
osing variant PTC, 2 minimally invasive FTCs, and 1
widely invasive FTC), 7 poorly differentiated carcinomas,
5 anaplastic carcinomas, and 9 medullary carcinomas.
PTC was defined as a classic type with tall cell features if
it consisted of less than 50 % tall cells and as a tall cell
variant if it consisted of 50 % or more tall cells [33].
Mutational analyses for BRAF and TERT promoter mutations
Genomic DNA was isolated from manually dissected
10-μm thick paraffin-embedded tissue sections using
the RecoverAll™ Total Nucleic Acid Isolation Kit (Life
Technologies, Carlsbad, CA, USA). Sanger sequencing
was performed to detect the presence of BRAF V600E and
TERT promoter mutations. Exon 15 of the BRAF gene
was PCR-amplified as previously reported using the
following forward primer (5′-TCATAATGCTTGCTCTG
ATAGGA-3′) and reverse primer (5′-GGCCAAAAATT
TAATCAGTGGA-3′), resulting in a 224 bp PCR product
[11, 33, 34]. A 193 bp fragment of the TERT promoter was
amplified by PCR as previously reported using the follow-
ing forward primer (5′-CACCCGTCCTGCCCCTTCAC
CTT-3′) and reverse primer (5′-GGCTTCCCACGTGCG
CAGCAGGA-3′) [35]. All TERT promoter mutations
were confirmed using another previously reported primer
set that included the following forward primer (5′-
AGTGGATTCGCGGGCACAGA-3′) and reverse primer
(5′-CAGCGCTGCCTGAAACTC-3′) and resulted in a
235 bp PCR product [21].
Immunohistochemistry for ALK overexpression
Immunohistochemistry was performed on paraffin-
embedded whole tissue sections of surgical specimens
using the ALK antibody (clone p80, Novocastra
Laboratories Ltd., Newcastle upon Tyne, UK) and the
Polink-2 HRP plus anti-rabbit DAB detection kit (GBI
Labs, Mukilteo, WA, USA). As a positive control, we
used paraffin-embedded tissue sections from two lung
adenocarcinomas with previously confirmed ALK re-
arrangement by fluorescence in situ hybridization (FISH).
FISH for ALK rearrangement
We performed FISH to detect ALK rearrangement using
a ZytoLight SPEC ALK Dual Color Break Apart Probe
and Kit (ZytoVision GmbH, Bremerhaven, Germany) ac-
cording to the manufacturer’s protocol [29]. The positive
criterion for ALK rearrangement was defined as > 15 %
of split signal separation and/or isolated red signal in at
least 100 tumor cells as previously described [26, 29].
Evaluation of response to radioiodine therapy
All 30 WDTC patients with distant metastasis underwent
radioactive iodine (RAI) therapy. The response to RAI
ablation was evaluated with a whole body iodine -131
scan, evaluation of serum thyroglobulin levels, and a
computerized tomography scan. Clinical outcomes to RAI
therapy were classified as complete remission (CR), partial
response (PR), stable disease (SD), and progressive disease
(PD) according to previously described criteria [36].
Statistical analysis
The Pearson’s chi-square test or Fisher’s exact test was
used to assess the relationship between two nominal
variables. The Student’s t-test and Mann–Whitney test
were used to compare two different groups of continu-
ous parametric or nonparametric data, respectively. For
the multivariate analysis, parameters that were signifi-
cant at p < 0.25 in the univariate analysis were included
in a multiple logistic regression test. Two-sided tests
with p < 0.05 were considered to be statistically signifi-
cant. Statistical analysis was performed with SPSS ver.
21.0 software (SPSS Inc., Chicago, IL, USA) and SAS
ver. 9.3 software (SAS Institute Inc., Cary, NC, USA).
Meta-analysis of the proportion of TERT promoter mutations
We searched the literature for TERT promoter muta-
tions in thyroid cancer using PubMed and Google up to
November 2015, and selected eligible articles. We then
conducted a meta-analysis of the proportion of TERT
promoter mutations according to the histologic types of
thyroid cancers. Cochran Q test and I2 values were
employed to assess statistical heterogeneity among
studies. If significant heterogeneity was observed (p < 0.10
or I2 > 50 %), the random effect model was used for meta-
analysis. Otherwise, we used a fixed-effect model for the
meta-analysis. Meta-analyses were performed using done
using MedCalc version 13.0.2 software (MedCalc, Ostend,
Belgium).
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Results
Prevalence of TERT promoter mutations, the BRAF V600E
mutation, and ALK rearrangement in thyroid cancers
TERT promoter mutations were found in 12 (40 %) of
30 WDTCs with distant metastasis, 2 (29 %) of 7 poorly
differentiated carcinomas, and 3 (60 %) of 5 anaplastic
carcinomas. However, no such mutations were present
in the 192 WDTCs without distant metastasis or the 9
medullar carcinomas (Table 1). Among TERT promoter
mutations, the most common type was C228T (76 %),
followed by C250T (18 %) and C250A (6 %) (Table 1)
(Fig. 1). Among 12 WDTCs with TERT promoter muta-
tions, the most frequent histologic subtype was the tall
cell variant of PTC (Table 1).
The BRAF V600E mutation was found in 142 (83 %)
of 172 PTCs without distant metastasis, 15 (56 %) of 27
PTCs with distant metastasis, 1 (14 %) of 7 poorly differ-
entiated carcinomas and 4 (80 %) of 5 anaplastic carcin-
omas (Table 1). However, the BRAF V600E mutation
was not found in 23 FTCs and 9 medullary carcinomas.
None of the 243 thyroid cancers had positive ALK im-
munohistochemistry or ALK break apart FISH (Table 1).
Relationship between TERT promoter mutations and
clinicopathologic features of WDTCs
In 222 patients with WDTC, the presence of TERT pro-
moter mutations was associated with older age (p = 0.017),
larger tumor size (p = 0.043), aggressive histologic sub-
types (p < 0.001), advanced pathologic T stage (p = 0.014),
extrathyroidal extension (p = 0.035), lymph node metasta-
sis (p = 0.011), lateral lymph node metastasis (p < 0.001),
distant metastasis (p < 0.001), and advanced AJCC
stage (p < 0.001) (Table 2). There was no association
between TERT promoter mutations and the BRAF
V600E mutation (Table 2).
Relationship between clinicopathologic and molecular
features and distant metastases of WDTCs
The mean follow-up period of the patients with WDTC
was 36.1 months. In 14 patients, distant metastases were
found within 6 months of first diagnosis. Distant me-
tastases occurred in the lung (n = 24), bone (n = 3),
lung and bone (n = 2), and brain (n = 1). Distant metastasis
was associated with larger tumor size (p = 0.001), ag-
gressive histologic subtype (p = 0.003), advanced pT
Table 1 TERT promoter mutations, BRAF V600E mutation and ALK rearrangement in 243 Korean patients with thyroid cancer
Patient TERT promoter mutation BRAF V600E ALK rearrangement
C228T C250A C250T Overall
WDTC without distant metastasis 192 0 0 0 0 142 (74 %) 0
PTC, classic 127 0 0 0 0 110 (87 %) 0
PTC, classic with TCF 11 0 0 0 0 10 (91 %) 0
PTC, EFV 9 0 0 0 0 1 (11 %) 0
PTC, IFV 7 0 0 0 0 5 (71 %) 0
PTC, tall cell 16 0 0 0 0 15 (94 %) 0
PTC, oncocytic 1 0 0 0 0 1 (100 %) 0
PTC, Warthin-like 1 0 0 0 0 0 0
FTC, minimally invasive 20 0 0 0 0 0 0
WDTC with distant metastasis 30 10 (33 %) 0 2 (7 %) 12 (40 %) 15 (50 %) 0
PTC, classic 14 3 (21 %) 0 0 3 (21 %) 7 (50 %) 0
PTC, classic with TCF 4 2 (50 %) 0 1 (25 %) 3 (75 %) 4 (100 %) 0
PTC, EFV 1 0 0 0 0 0 0
PTC, macrofollicular 1 0 0 0 0 0 0
PTC, tall cell 5 4 (80 %) 0 0 4 (80 %) 3 (60 %) 0
PTC, columnar cell 1 0 0 1 (100 %) 1 (100 %) 1 (100 %) 0
PTC, diffuse sclerosing 1 0 0 0 0 0 0
FTC, minimally invasive 2 1 (50 %) 0 0 0 0 0
FTC, widely invasive 1 0 0 0 1(100 %) 0 0
Poorly differentiated carcinoma 7 1 (14 %) 1 (14 %) 0 2 (29 %) 1 (14 %) 0
Anaplastic carcinoma 5 2 (40 %) 0 1 (20 %) 3 (60 %) 4 (80 %) 0
Medullary carcinoma 9 0 0 0 0 0 0
WDTC well-differentiated thyroid carcinoma, PTC papillary thyroid carcinoma, TCF tall cell features, EFV encapsulated follicular variant, IFV infiltrative follicular variant,
FTC follicular thyroid carcinoma
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stage (p < 0.001), extrathyroidal extension (p = 0.001),
lymph node metastasis (p < 0.001), lateral lymph node
metastasis (p < 0.001) and the TERT promoter mutation
(p < 0.001). However, the BRAF V600E mutation was
inversely associated with distant metastasis (p = 0.007).
In the multivariate analysis, the odds ratio (OR) for
distant metastasis of WDTC in patients harboring
tumors with TERT promoter mutations and lateral
lymph node metastases was 155.298 (95 % confidence
interval (CI) 3.362–999.990) and 11.159 (95 % CI
1.902–65.461), respectively (Table 3). The OR for dis-
tant metastases of WDTC in patients harboring
tumors with the BRAF V600E mutation was 0.083
(95 % CI 0.021–0.327) (Table 3).
Impact of molecular genotypes on response of metastatic
WDTCs to RAI therapy
Of the 30 WDTCs with distant metastasis, 9 (30 %) had
coexisting BRAF V600E and TERT promoter mutations
and 12 (40 %), including follicular and diffuse sclerosing
variants of PTC, had no mutations (Fig. 2a).
The structural response of distant metastatic disease
to RAI was evaluated at least 6 months after RAI ther-
apy. Of the 30 WDTC patients with distant metastasis,
six (20 %) patients had PR and six (20 %) had SD after
RAI ablation whereas none achieved CR and 18 (60 %)
had PD. There was a significant correlation between
tumors with the BRAF V600E mutation alone and the
progression of distant metastatic disease after RAI ther-
apy (p = 0.025), but TERT promoter mutations alone
were not associated with PD (Fig. 2b). PR or SD after RAI
therapy was significantly more likely in patients with wild-
type BRAF and TERT promoter genes (p = 0.024) (Fig. 2b).
However, other combinations of genetic mutations were
not correlated with RAI response.
Meta-analysis of TERT promoter mutation prevalence in
thyroid cancer
Our study and 13 articles were included for the meta-
analysis of TERT promoter mutation prevalence in various
thyroid cancers [17, 18, 21, 24, 25, 32, 37–43]. Significant
heterogeneity was found in classic PTC, FTC, Hürthle cell
carcinoma, and anaplastic carcinoma among the studies
(Figs. 3 and 4). The mean frequencies of TERT promoter
mutations in PTC, conventional FTC, Hürthle cell carcin-
oma, poorly differentiated carcinoma and anaplastic
carcinoma were 11.3 % (95 % CI 9.3–13.5), 21.3 % (95 %
CI 14.2–29.4), 6.7 % (95 % CI 0.2–21.4), 39.6 % (95 % CI
31.3–48.2), and 38.5 % (95 % CI 32.6–44.7), respectively
(Figs. 3 and 4). When PTCs were stratified by histologic
subtype, mean frequencies of TERT promoter mutations
Table 2 Association between TERT promoter mutations and








Age (mean years) 45.5 ± 13.3 55.0 ± 11.8 0.017
Gender
Female 164 (94.8 %) 9 (5.2 %) 0.801
Male 46 (93.9 %) 3 (6.1 %)
Tumor size (mean mm) 14.8 ± 12.5 31.9 ± 22.9 0.043
Histologic types
Aggressive varianta) 18 (75.0 %) 6 (25.0 %) <0.001
Less-aggressive variant 192 (97.0 %) 6 (3.0 %)
Pathologic T stage
pT 1–2 97 (99.0 %) 1 (1.0 %) 0.014
pT 3–4 113 (91.1 %) 11 (8.9 %)
Extrathyroidal extension
Absent 105 (98.1 %) 2 (1.9 %) 0.035
Present 105 (91.3 %) 10 (8.7 %)
Pathologic N stage
pN0 105 (99.1 %) 1 (0.9 %) 0.011
pN1 105 (91.3 %) 10 (8.7 %)
Lateral lymph node metastasis
Absent 166 (98.8 %) 2 (1.2 %) <0.001
Present 43 (82.7 %) 9 (17.3 %)
Distant metastasis
Absent 192 (100 %) 0 <0.001
Present 18 (60.0 %) 12 (40 %)
AJCC stage
I-II 120 (100 %) 0 <0.001
III-IV 90 (88.2 %) 12 (11.8 %)
BRAF V600E mutation
Absent 62 (95.4 %) 3 (4.6 %) 0.738
Present 148 (94.3 %) 9 (5.7 %)
a)Aggressive variant includes 21 tall cell, 1 columnar cell, and 1 diffuse sclerosing
variant of papillary carcinoma and 1 widely invasive follicular carcinoma
Table 3 Multivariate analysis of factors affecting distant metastasis
Odds Ratio 95 % CI p-value
Age 1.046 0.999–1.095 0.054
Gender 0.688 0.197–2.401 0.557
Tumor size 1.04 0.999–1.095 0.083
Histologic type 0.816 0.182–3.66 0.790
Pathologic T stage 0.142 0.005–4.016 0.252
Extrathyroidal extension 19.535 0.618–617.017 0.091
Pathologic N stage 0.922 0.141–6.053 0.933
Lateral lymph node metastasis 11.159 1.902–65.461 0.008
TERT promoter mutation 155.298 3.362–999.990 0.009
BRAF V600E mutation 0.083 0.021–0.327 <0.001
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in classic, follicular, and tall cell variants were 8.8 % (95 %
CI 6.8–11.1), 6.6 % (95 % CI 4.5–9.3), 27.5 % (95 % CI
21.0–34.7), respectively (Fig. 3). TERT promoter muta-
tions were not found in a total of 132 medullary carcin-
oma patients including our case series [17, 21, 24, 25, 41].
Discussion
We found that TERT promoter mutations are prevalent
in aggressive thyroid cancers and are associated with
distant metastasis of WDTCs in Korean patients with a
high prevalence of the BRAF V600E mutation. When we
examined TERT promoter mutations in a consecutive
series of 192 WDTC patients who had no distant metas-
tasis during the follow-up period, none carried the mu-
tation. However, TERT promoter mutations were found
in 40 % of WDTC patients with distant metastasis. In all
222 WDTC patients, the overall prevalence of TERT
promoter mutations was 5.4 %. These results are lower
than those reported in other countries. The prevalence
of TERT promoter mutations reported in the literature
ranged from 7.3 to 25.5 % in PTC and from 4.3 to
36.4 % in FTC [17, 18, 21, 24, 25, 32, 37–43].
In our study, TERT promoter mutations were associated
with older age, larger tumors, higher stage and distant
metastases in WDTCs. These findings are consistent with
those of previous reports indicating that TERT promoter
mutations are associated with aggressive clinical behavior
[21, 24]. In the stratified meta-analysis by histologic
subtype of PTC, we found that the prevalence of TERT
promoter mutations was correlated with the degree of
tumor aggressiveness. The tall cell variant of PTC exhibits
more aggressive behavior than classic PTC [27, 33], while
clinical features of the follicular variant of PTC are
between classic PTC and FTC [44]. The TERT promoter
mutations were most frequently found in tall cell variant
(27.5 %, 95 % CI 21.0–34.7), followed by classic PTC
(8.8 %, 95 % CI 6.8–11.1) and follicular variant (6.6 %,
6 classic PTCs
2 follicular PTCs
1 tall cell PTC
1 diffuse sclerosing PTC
2 FTCs
TERT (-) / BRAF (-) 40%
2 classic PTCs
3 classic PTCs with TCF
3 tall cell PTCs
1 columnar cell  PTC
TERT (+) / BRAF (+) 30%
5 classic PTCs
1 classic PTC with TCF
TERT (-) / BRAF (+) 20%
1 classic PTC
1 tall cell PTC
1 FTC























progressive diasease partial remission or stable disease
p = 0.260      p = 0.025        p = 0.249       p = 1.000      p = 0.358        p = 0.024
a
b
Fig. 2 Molecular genotypes and radioactive iodine therapy. a Molecular genotypes of 30 well-differentiated thyroid carcinomas with distant metastases
based on TERT promoter mutations and BRAF V600E. b Structural response of distant metastatic disease to radioactive iodine therapy classified
by molecular genotypes in 30 well-differentiated thyroid carcinoma patients with distant metastasis. PTC, papillary thyroid carcinoma; TCF, tall
cell features; FTC, follicular thyroid carcinoma; TERT, TERT promoter mutations; BRAF, BRAF V600E; (+), mutation positive; (-), mutation negative
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95 % CI 4.5–9.3). These results are consistent with find-
ings of present study.
Many studies have shown the role of BRAF V600E
in advanced clinical stage and distant metastasis of
PTC [7, 45]. In contrast, we found that the BRAF
V600E status was inversely correlated with the rate of
distant metastasis in WDTCs. This contradiction may
be related to case selection bias. Of 30 metastatic
tumors enrolled in our study, 20 % included follicular
and diffuse sclerosing variants of PTC and FTCs,
which were all negative for the BRAF V600E muta-
tion. It is well-known that the incidence of BRAF
V600E is very low in the follicular and diffuse scleros-
ing variants of PTC, and no FTCs have the BRAF
V600E mutation [11, 34, 46].
In our study, the BRAF V600E mutation was signifi-
cantly associated with low response rate of metastatic
WDTCs to RAI therapy. These results are consistent
with previous studies that have demonstrated high
frequency of BRAFV600E mutation in RAI-refractory
metastatic thyroid cancers [1, 47]. However, there was
no significant effect of TERT promoter mutations on
distant metastasis of WDTCs. The most likely mechan-
ism of resistance to RAI therapy is the impaired iodide-
handling machinery in metastatic thyroid cancer [1].
Many studies have reported that BRAFV600E mutation
reduces the expression of thyroid iodine-handling genes
(sodium iodide symporter, thyroid-stimulating hormone
receptor, thyroglobulin, and thyroperoxidase) in thyroid
cancer [1, 47, 48]. However, mechanism underlying the
RAI therapy resistance associated with TERT promoter
mutations remains uncertain. Xing et al reported that
coexisting BRAF V600E and TERT C228T mutations
defined the most aggressive subgroup of PTC when
analyzed in terms of clinicopathologic features, tumor
recurrence and disease-free survival rate [18]. We did
not observe this trend in our study (data not shown).
Two TERT C228T and C250T mutations create con-
sensus binding motifs for the E-twenty-six (ETS)/ternary
complex transcription factor (TCF) and increase the
transcriptional activity of the TERT promoter [19, 23].
TERT promoter mutations in thyroid cancer and glioma
were associated with increased mRNA expression and
telomerase activity [17, 49]. BRAF V600E and TERT
promoter mutations can activate the mitogen-activated
protein kinase (MAPK) signaling pathway in thyroid
cancer [21]. In previous studies, TERT promoter muta-
tions were more frequently found in BRAF V600E
mutation-positive PTCs, suggesting an incremental and
synergistic effect of the coexisting two mutations in
a bAll PTC Classic PTC
Follicular variant Tall cell variantc d
Study n Proportion 95% CI
Liu X (2013) 257 11.7% 8.0 to 16.2
Landa (2013) 80 22.5 % 13.9 to 33.2
Liu T (2013) 51 25.5 % 14.3 to 39.6
Vinagre (2013) 169 7.7 % 4.2 to 12.8
Xing (2014)* 507 12.0 % 9.3 to 15.2
Liu X (2014) 408 11.3 % 8.4 to 14.8
Melo (2014) 332 7.5 % 4.9 to 10.9
Muzza (2014) 182 12.1 % 7.7 to 17.7
TCGA (2014) 384 9.4 % 6.7 to 12.7
Gandolfi (2015) 121 17.4 % 11.1 to 25.3
Dettmer (2015) 110 7.3 % 3.2 to 13.9
Qasem (2015) 243 11.1 % 7.5 to 15.8
Present study 199 5.5 % 2.8 to 9.7
Total (fixed effects) 3043 10.8 % 9.7 to 12.0
Total (random effects) 3043 11.3 % 9.3 to 13.5
Study n Proportion 95% CI
Liu X (2013) 187 12.3 % 8.0 to 17.9
Vinagre (2013) 110 10.9 % 5.8 to 18.3
Xing (2014)* 383 12.3 % 9.2 to 16.0
Liu X (2014) 408 11.3 % 8.4 to 14.8
Melo (2014) 230 8.3 % 5.0 to 12.6
TCGA (2014) 246 8.9 % 5.7 to 13.3
Gandolfi (2015) 66 9.1 % 3.4 to 18.8
Dettmer (2015) 91 2.2 % 0.3 to 7.7
Qasem (2015) 153 6.5 % 3.2 to 11.7
Present study 156 3.8 % 1.4 to 8.2
Total (fixed effects) 2030 9.5 % 8.2 to 10.8
Total (random effects) 2030 8.8 % 6.8 to 11.1
I
2
= 62.9% p = 0.004I
2
= 68.4% p < 0.001
Study n Proportion 95% CI
Liu X (2013) 56 3.6 % 0.4 to 12.3
Vinagre (2013) 39 0.0 % 0.0 to 9.0
Xing (2014)* 103 7.8 % 3.4 to 14.7
Melo (2014) 74 6.8 % 2.2 to 15.1
TCGA (2014) 81 6.2 % 2.0 to 13.8
Gandolfi (2015) 15 13.3 % 1.7 to 40.5
Qasem (2015) 56 12.5 % 5.2 to 24.1
Present study 18 0.0 % 0.0 to 18.5
Total (fixed effects) 442 6.6 % 4.5 to 9.3
Total (random effects) 442 6.4 % 3.7 to 9.8
I
2
= 0.0% p = 0.907I
2
= 41.4% p = 0.102
Study n Proportion 95% CI
Liu X (2013) 13 30.8 % 9.1 to 61.4
Xing (2014)* 19 26.3 % 9.1 to 51.2
Melo (2014) 2 0.0 % 0.0 to 84.2
TCGA (2014) 29 20.7 % 8.0 to 39.7
Gandolfi (2015) 35 31.4 % 16.9 to 49.3
Dettmer (2015) 19 31.6 % 12.6 to 56.6
Qasem (2015) 30 30.0 % 14.7 to 49.4
Present study 21 19.0 % 5.4 to 41.9
Total (fixed effects) 168 27.5 % 21.0 to 34.7
Total (random effects) 168 27.5 % 21.2 to 34.3
Fig. 3 Forest plots of the meta-analysis for the prevalence of TERT promoter mutations in all papillary thyroid carcinomas (PTC), classic PTC (b),
follicular variant of PTC (c), and tall cell variant of PTC (d). *Only TERT C228T was examined. TCGA, The Cancer Genome Atlas
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tumorigenesis [18, 21]. In our study, the TERT promoter
mutation status was not associated with the incidence of
the BRAF V600E mutation. These discrepancies may be
associated with ethnic differences given that there is a
higher prevalence of the BRAF V600E mutation and
lower occurrence of TERT promoter mutations in Korean
patients than in Western patients. Therefore, our study
results cannot be generalized to other populations.
We found no TERT promoter mutations in medullary
carcinoma. This finding is consistent with previous
reports [21, 24]. Moreover, TERT promoter mutations
were not found in benign thyroid nodules, whereas they
were more prevalent in poorly differentiated or anaplastic
carcinomas than in WDTCs [21, 24]. Therefore, it is
suggested that TERT promoter mutations are involved
only in the tumorigenesis of follicular-cell derived thyroid
cancers, particularly in aggressive subtypes, and may occur
as a late molecular-genetic event that induces dedifferenti-
ation of WDTCs [21].
ALK gene rearrangements are mutually exclusive with
all other known thyroid cancer driver mutations and
have been reported in up to 2.2 % of PTCs, 4 % of poorly
differentiated carcinomas, and 4 % of anaplastic carcin-
omas [26, 28, 32]. In our study, ALK rearrangement was
not identified in any thyroid cancers.
The main limitations of our study were the relatively
small sample size of metastatic cancers and the short
follow-up period. Although the analyses for disease
recurrence and survival of patients were not available,
we could evaluate the therapeutic response to RAI based
on the distant metastatic disease genotypes. We report
for the first time the clinical impact of TERT promoter
mutations on thyroid cancers that occur in a BRAF
V600E prevalent area.
Conclusions
Our study demonstrated that Korean patients have a
higher BRAF V600E prevalence and lower prevalence of
the TERT promoter mutation and ALK rearrangement in
thyroid cancers than do Western patients. TERT promoter
mutation is associated with aggressive clinicopathologic
features and is a strong predictor of distant metastasis of
WDTC. In Korea, the BRAF V600E-negative WDTCs
more frequently develop distant metastasis than BRAF
V600E-positive tumors. When WDTC patients develop
distant metastases, RAI therapy is most effective in
patients without BRAF V600E and TERT promoter
mutations. Further prospective evaluation that includes a
larger sample size is needed.
a bFollicular carcinoma Hürthle cell carcinoma
Poorly differentiated carcinoma Anaplastic carcinomac d
Study n Proportion 95% CI
Liu X (2013) 79 13.9 % 7.2 to 23.6
Liu T (2013) 36 22.2 % 10.1 to 39.2
Vinagre (2013) 36 25.0 % 12.1 to 42.2
Liu X (2014) 22 36.4 % 17.2 to 59.3
Melo (2014) 43 27.9 % 15.3 to 43.7
Qasem (2015) 5 20.0 % 0.5 to 71.6
Present study 23 4.3 % 0.1 to 21.9
Total (fixed effects) 244 20.6 % 15.7 to 26.1
Total (random effects) 244 21.3 % 14.2 to 29.4
Study n Proportion 95% CI
Landa (2013) 25 16.0% 4.5 to 36.1
Vinagre (2013) 28 0.0 % 0.0 to 12.3
Melo (2014) 27 0.0 % 0.0 to 12.8
Qasem (2015) 3 33.3 % 0.8 to 90.6
Total (fixed effects) 83 4.8 % 1.4 to 11.6
Total (random effects) 83 6.7 % 0.2 to 21.4
I
2
= 73.1% p = 0.012I
2
= 50.5% p = 0.060
Study n Proportion 95% CI
Liu X (2013) 8 37.5% 8.5 to 75.5
Landa (2013) 58 51.7% 38.2 to 65.0
Vinagre (2013) 14 21.4% 4.7 to 50.8
Melo (2014) 31 29.0% 14.2 to 48.0
Qasem (2015) 14 35.7% 12.8 to 64.9
Present study 7 28.6% 3.7 to 71.0
Total (fixed effects) 132 39.6% 31.3 to 48.2
Total (random effects) 132 37.4% 27.4 to 48.1
I
2
= 44.3% p = 0.096I
2
= 29.6% p = 0.213
Study n Proportion 95% CI
Liu X (2013) 54 46.3% 32.6 to 60.4
Landa (2013) 20 50.0% 27.2 to 72.8
Liu T (2013) 20 50.0% 27.2 to 72.8
Vinagre (2013) 16 12.5% 1.6 to 38.3
Melo (2014) 36 33.3% 18.6 to 51.0
Shi (2015) 106 34.9% 25.9 to 44.8
Present study 5 60.0% 14.7 to 94.7
Total (fixed effects) 257 38.5% 32.6 to 44.7
Total (random effects) 257 39.2% 30.6 to 48.1
Fig. 4 Forest plots of the meta-analysis for the prevalence of TERT promoter mutations in follicular thyroid carcinomas (a), Hürthle cell carcinoma
(b), poorly differentiated carcinoma (c), and anaplastic carcinoma (d)
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